http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 24 Feb 2026 07:30:17 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Radiopharm+Theranostics+doses+first+patient+in+cancer+drug+trial/26046735.html <p>Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) announced it administered the first dose of its experimental cancer treatment 177Lu-BetaBart to a patient in a phase 1/2a clinical trial.</p> <p>The dose escalation and expansion trial will evaluate the safety, biodistribution and radiation dosimetry of 177Lu-BetaBart, along with preliminary anti-tumor activity in patients with advanced solid tumors. The study aims to enroll 61 participants with various cancer types including prostate, colorectal, lung, breast and ovarian cancers.</p> <p>177Lu-BetaBart represents the first radiotherapeutic agent developed by Radiopharm Ventures, a joint venture between Radiopharm Theranostics and The University of Texas MD Anderson Cancer Center. The treatment consists of http://www.streetinsider.com/FDA/Radiopharm+Theranostics+doses+first+patient+in+cancer+drug+trial/26046735.html Tue, 24 Feb 2026 07:30:17 -0500 A.33615634 A.50205822 O.00061097 O.07116439 O.49874572 RAD RADX http://www.streetinsider.com/FDA/Radiopharm+Theranostics+doses+first+patient+in+cancer+drug+trial/26046735.html <p>Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) announced it administered the first dose of its experimental cancer treatment 177Lu-BetaBart to a patient in a phase 1/2a clinical trial.</p> <p>The dose escalation and expansion trial will evaluate the safety, biodistribution and radiation dosimetry of 177Lu-BetaBart, along with preliminary anti-tumor activity in patients with advanced solid tumors. The study aims to enroll 61 participants with various cancer types including prostate, colorectal, lung, breast and ovarian cancers.</p> <p>177Lu-BetaBart represents the first radiotherapeutic agent developed by Radiopharm Ventures, a joint venture between Radiopharm Theranostics and The University of Texas MD Anderson Cancer Center. The treatment consists of http://www.streetinsider.com/FDA/Radiopharm+Theranostics+doses+first+patient+in+cancer+drug+trial/26046735.html Tue, 24 Feb 2026 07:30:17 -0500 A.33615634 A.50205822 O.00061097 O.07116439 O.49874572 RAD RADX http://www.streetinsider.com/FDA/Radiopharm+Theranostics+doses+first+patient+in+cancer+drug+trial/26046735.html <p>Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) announced it administered the first dose of its experimental cancer treatment 177Lu-BetaBart to a patient in a phase 1/2a clinical trial.</p> <p>The dose escalation and expansion trial will evaluate the safety, biodistribution and radiation dosimetry of 177Lu-BetaBart, along with preliminary anti-tumor activity in patients with advanced solid tumors. The study aims to enroll 61 participants with various cancer types including prostate, colorectal, lung, breast and ovarian cancers.</p> <p>177Lu-BetaBart represents the first radiotherapeutic agent developed by Radiopharm Ventures, a joint venture between Radiopharm Theranostics and The University of Texas MD Anderson Cancer Center. The treatment consists of http://www.streetinsider.com/FDA/Radiopharm+Theranostics+doses+first+patient+in+cancer+drug+trial/26046735.html Tue, 24 Feb 2026 07:30:17 -0500 A.33615634 A.50205822 O.00061097 O.07116439 O.49874572 RAD RADX http://www.streetinsider.com/FDA/Radiopharm+Theranostics+doses+first+patient+in+cancer+drug+trial/26046735.html <p>Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) announced it administered the first dose of its experimental cancer treatment 177Lu-BetaBart to a patient in a phase 1/2a clinical trial.</p> <p>The dose escalation and expansion trial will evaluate the safety, biodistribution and radiation dosimetry of 177Lu-BetaBart, along with preliminary anti-tumor activity in patients with advanced solid tumors. The study aims to enroll 61 participants with various cancer types including prostate, colorectal, lung, breast and ovarian cancers.</p> <p>177Lu-BetaBart represents the first radiotherapeutic agent developed by Radiopharm Ventures, a joint venture between Radiopharm Theranostics and The University of Texas MD Anderson Cancer Center. The treatment consists of http://www.streetinsider.com/FDA/Radiopharm+Theranostics+doses+first+patient+in+cancer+drug+trial/26046735.html Tue, 24 Feb 2026 07:30:17 -0500 A.33615634 A.50205822 O.00061097 O.07116439 O.49874572 RAD RADX http://www.streetinsider.com/FDA/Radiopharm+Theranostics+doses+first+patient+in+cancer+drug+trial/26046735.html <p>Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) announced it administered the first dose of its experimental cancer treatment 177Lu-BetaBart to a patient in a phase 1/2a clinical trial.</p> <p>The dose escalation and expansion trial will evaluate the safety, biodistribution and radiation dosimetry of 177Lu-BetaBart, along with preliminary anti-tumor activity in patients with advanced solid tumors. The study aims to enroll 61 participants with various cancer types including prostate, colorectal, lung, breast and ovarian cancers.</p> <p>177Lu-BetaBart represents the first radiotherapeutic agent developed by Radiopharm Ventures, a joint venture between Radiopharm Theranostics and The University of Texas MD Anderson Cancer Center. The treatment consists of http://www.streetinsider.com/FDA/Radiopharm+Theranostics+doses+first+patient+in+cancer+drug+trial/26046735.html Tue, 24 Feb 2026 07:30:17 -0500 A.33615634 A.50205822 O.00061097 O.07116439 O.49874572 RAD RADX http://www.streetinsider.com/FDA/Radiopharm+Theranostics+doses+first+patient+in+cancer+drug+trial/26046735.html <p>Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) announced it administered the first dose of its experimental cancer treatment 177Lu-BetaBart to a patient in a phase 1/2a clinical trial.</p> <p>The dose escalation and expansion trial will evaluate the safety, biodistribution and radiation dosimetry of 177Lu-BetaBart, along with preliminary anti-tumor activity in patients with advanced solid tumors. The study aims to enroll 61 participants with various cancer types including prostate, colorectal, lung, breast and ovarian cancers.</p> <p>177Lu-BetaBart represents the first radiotherapeutic agent developed by Radiopharm Ventures, a joint venture between Radiopharm Theranostics and The University of Texas MD Anderson Cancer Center. The treatment consists of http://www.streetinsider.com/FDA/Radiopharm+Theranostics+doses+first+patient+in+cancer+drug+trial/26046735.html Tue, 24 Feb 2026 07:30:17 -0500 A.33615634 A.50205822 O.00061097 O.07116439 O.49874572 RAD RADX http://www.streetinsider.com/FDA/Radiopharm+Theranostics+doses+first+patient+in+cancer+drug+trial/26046735.html <p>Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) announced it administered the first dose of its experimental cancer treatment 177Lu-BetaBart to a patient in a phase 1/2a clinical trial.</p> <p>The dose escalation and expansion trial will evaluate the safety, biodistribution and radiation dosimetry of 177Lu-BetaBart, along with preliminary anti-tumor activity in patients with advanced solid tumors. The study aims to enroll 61 participants with various cancer types including prostate, colorectal, lung, breast and ovarian cancers.</p> <p>177Lu-BetaBart represents the first radiotherapeutic agent developed by Radiopharm Ventures, a joint venture between Radiopharm Theranostics and The University of Texas MD Anderson Cancer Center. The treatment consists of http://www.streetinsider.com/FDA/Radiopharm+Theranostics+doses+first+patient+in+cancer+drug+trial/26046735.html Tue, 24 Feb 2026 07:30:17 -0500 A.33615634 A.50205822 O.00061097 O.07116439 O.49874572 RAD RADX http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html <p align="center"><em>First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center </em></p> <p align="center"><em>Preclinical animal studies of BetaBart (RV-01) have demonstrated tumor shrinkage and prolonged survival </em></p> <p>SYDNEY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the dosing of the first patient in its First-In-Human (FIH) Phase 1/2a clinical trial of 177Lu-Betabart (RV-01).</p> <p>The Phase 1/2a clinical trial is a dose escalation and expansion http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html Tue, 24 Feb 2026 07:30:00 -0500 A.33615634 A.50205822 O.00061097 O.07116439 O.49874572 RAD RADX http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html <p align="center"><em>First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center </em></p> <p align="center"><em>Preclinical animal studies of BetaBart (RV-01) have demonstrated tumor shrinkage and prolonged survival </em></p> <p>SYDNEY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the dosing of the first patient in its First-In-Human (FIH) Phase 1/2a clinical trial of 177Lu-Betabart (RV-01).</p> <p>The Phase 1/2a clinical trial is a dose escalation and expansion http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html Tue, 24 Feb 2026 07:30:00 -0500 A.33615634 A.50205822 O.00061097 O.07116439 O.49874572 RAD RADX http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html <p align="center"><em>First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center </em></p> <p align="center"><em>Preclinical animal studies of BetaBart (RV-01) have demonstrated tumor shrinkage and prolonged survival </em></p> <p>SYDNEY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the dosing of the first patient in its First-In-Human (FIH) Phase 1/2a clinical trial of 177Lu-Betabart (RV-01).</p> <p>The Phase 1/2a clinical trial is a dose escalation and expansion http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html Tue, 24 Feb 2026 07:30:00 -0500 A.33615634 A.50205822 O.00061097 O.07116439 O.49874572 RAD RADX http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html <p align="center"><em>First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center </em></p> <p align="center"><em>Preclinical animal studies of BetaBart (RV-01) have demonstrated tumor shrinkage and prolonged survival </em></p> <p>SYDNEY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the dosing of the first patient in its First-In-Human (FIH) Phase 1/2a clinical trial of 177Lu-Betabart (RV-01).</p> <p>The Phase 1/2a clinical trial is a dose escalation and expansion http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html Tue, 24 Feb 2026 07:30:00 -0500 A.33615634 A.50205822 O.00061097 O.07116439 O.49874572 RAD RADX http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html <p align="center"><em>First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center </em></p> <p align="center"><em>Preclinical animal studies of BetaBart (RV-01) have demonstrated tumor shrinkage and prolonged survival </em></p> <p>SYDNEY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the dosing of the first patient in its First-In-Human (FIH) Phase 1/2a clinical trial of 177Lu-Betabart (RV-01).</p> <p>The Phase 1/2a clinical trial is a dose escalation and expansion http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html Tue, 24 Feb 2026 07:30:00 -0500 A.33615634 A.50205822 O.00061097 O.07116439 O.49874572 RAD RADX http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html <p align="center"><em>First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center </em></p> <p align="center"><em>Preclinical animal studies of BetaBart (RV-01) have demonstrated tumor shrinkage and prolonged survival </em></p> <p>SYDNEY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the dosing of the first patient in its First-In-Human (FIH) Phase 1/2a clinical trial of 177Lu-Betabart (RV-01).</p> <p>The Phase 1/2a clinical trial is a dose escalation and expansion http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html Tue, 24 Feb 2026 07:30:00 -0500 A.33615634 A.50205822 O.00061097 O.07116439 O.49874572 RAD RADX http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html <p align="center"><em>First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center </em></p> <p align="center"><em>Preclinical animal studies of BetaBart (RV-01) have demonstrated tumor shrinkage and prolonged survival </em></p> <p>SYDNEY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the dosing of the first patient in its First-In-Human (FIH) Phase 1/2a clinical trial of 177Lu-Betabart (RV-01).</p> <p>The Phase 1/2a clinical trial is a dose escalation and expansion http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html Tue, 24 Feb 2026 07:30:00 -0500 A.33615634 A.50205822 O.00061097 O.07116439 O.49874572 RAD RADX http://www.streetinsider.com/Globe+Newswire/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html <p align="center"><em>First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center </em></p> <p align="center"><em>Preclinical animal studies of BetaBart (RV-01) have demonstrated tumor shrinkage and prolonged survival </em></p> <p>SYDNEY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the dosing of the first patient in its First-In-Human (FIH) Phase 1/2a clinical trial of 177Lu-Betabart (RV-01).</p> <p>The Phase 1/2a clinical trial is a dose escalation and expansion http://www.streetinsider.com/Globe+Newswire/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html Tue, 24 Feb 2026 07:30:00 -0500 A.33615634 A.50205822 O.00061097 O.07116439 O.49874572 RAD RADX http://www.streetinsider.com/Globe+Newswire/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html <p align="center"><em>First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center </em></p> <p align="center"><em>Preclinical animal studies of BetaBart (RV-01) have demonstrated tumor shrinkage and prolonged survival </em></p> <p>SYDNEY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the dosing of the first patient in its First-In-Human (FIH) Phase 1/2a clinical trial of 177Lu-Betabart (RV-01).</p> <p>The Phase 1/2a clinical trial is a dose escalation and expansion http://www.streetinsider.com/Globe+Newswire/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html Tue, 24 Feb 2026 07:30:00 -0500 A.33615634 A.50205822 O.00061097 O.07116439 O.49874572 RAD RADX http://www.streetinsider.com/Globe+Newswire/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html <p align="center"><em>First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center </em></p> <p align="center"><em>Preclinical animal studies of BetaBart (RV-01) have demonstrated tumor shrinkage and prolonged survival </em></p> <p>SYDNEY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the dosing of the first patient in its First-In-Human (FIH) Phase 1/2a clinical trial of 177Lu-Betabart (RV-01).</p> <p>The Phase 1/2a clinical trial is a dose escalation and expansion http://www.streetinsider.com/Globe+Newswire/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html Tue, 24 Feb 2026 07:30:00 -0500 A.33615634 A.50205822 O.00061097 O.07116439 O.49874572 RAD RADX http://www.streetinsider.com/Globe+Newswire/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html <p align="center"><em>First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center </em></p> <p align="center"><em>Preclinical animal studies of BetaBart (RV-01) have demonstrated tumor shrinkage and prolonged survival </em></p> <p>SYDNEY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the dosing of the first patient in its First-In-Human (FIH) Phase 1/2a clinical trial of 177Lu-Betabart (RV-01).</p> <p>The Phase 1/2a clinical trial is a dose escalation and expansion http://www.streetinsider.com/Globe+Newswire/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html Tue, 24 Feb 2026 07:30:00 -0500 A.33615634 A.50205822 O.00061097 O.07116439 O.49874572 RAD RADX http://www.streetinsider.com/Globe+Newswire/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html <p align="center"><em>First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center </em></p> <p align="center"><em>Preclinical animal studies of BetaBart (RV-01) have demonstrated tumor shrinkage and prolonged survival </em></p> <p>SYDNEY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the dosing of the first patient in its First-In-Human (FIH) Phase 1/2a clinical trial of 177Lu-Betabart (RV-01).</p> <p>The Phase 1/2a clinical trial is a dose escalation and expansion http://www.streetinsider.com/Globe+Newswire/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html Tue, 24 Feb 2026 07:30:00 -0500 A.33615634 A.50205822 O.00061097 O.07116439 O.49874572 RAD RADX http://www.streetinsider.com/Globe+Newswire/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html <p align="center"><em>First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center </em></p> <p align="center"><em>Preclinical animal studies of BetaBart (RV-01) have demonstrated tumor shrinkage and prolonged survival </em></p> <p>SYDNEY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the dosing of the first patient in its First-In-Human (FIH) Phase 1/2a clinical trial of 177Lu-Betabart (RV-01).</p> <p>The Phase 1/2a clinical trial is a dose escalation and expansion http://www.streetinsider.com/Globe+Newswire/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html Tue, 24 Feb 2026 07:30:00 -0500 A.33615634 A.50205822 O.00061097 O.07116439 O.49874572 RAD RADX http://www.streetinsider.com/Globe+Newswire/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html <p align="center"><em>First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center </em></p> <p align="center"><em>Preclinical animal studies of BetaBart (RV-01) have demonstrated tumor shrinkage and prolonged survival </em></p> <p>SYDNEY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the dosing of the first patient in its First-In-Human (FIH) Phase 1/2a clinical trial of 177Lu-Betabart (RV-01).</p> <p>The Phase 1/2a clinical trial is a dose escalation and expansion http://www.streetinsider.com/Globe+Newswire/Radiopharm+Theranostics+Doses+First+Patient+in+Phase+12a+Clinical+Study+of+BetaBart+%28RV-01%29/26046712.html Tue, 24 Feb 2026 07:30:00 -0500 A.33615634 A.50205822 O.00061097 O.07116439 O.49874572 RAD RADX http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Reports+Half-Year+Financial+Results+and+Business+Updates/25903754.html <p align="center"><em>Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases </em></p> <p align="center"><em>Interim data from additional Cohorts of the Phase 1 clinical trial of RAD 202 and RAD 204 in advanced solid tumors are expected in mid-2026</em></p> <p align="center"><em>Cash and cash equivalents of approximately $34.52 million provide runway into 2027 to advance pipeline of high value radiotherapeutic programs through key clinical and regulatory milestones</em></p> <p>SYDNEY, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Reports+Half-Year+Financial+Results+and+Business+Updates/25903754.html Wed, 28 Jan 2026 07:00:00 -0500 A.06822034 A.33615634 A.50205822 O.00061097 O.07116439 O.20026344 O.49874572 RAD RADX http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Reports+Half-Year+Financial+Results+and+Business+Updates/25903754.html <p align="center"><em>Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases </em></p> <p align="center"><em>Interim data from additional Cohorts of the Phase 1 clinical trial of RAD 202 and RAD 204 in advanced solid tumors are expected in mid-2026</em></p> <p align="center"><em>Cash and cash equivalents of approximately $34.52 million provide runway into 2027 to advance pipeline of high value radiotherapeutic programs through key clinical and regulatory milestones</em></p> <p>SYDNEY, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Reports+Half-Year+Financial+Results+and+Business+Updates/25903754.html Wed, 28 Jan 2026 07:00:00 -0500 A.06822034 A.33615634 A.50205822 O.00061097 O.07116439 O.20026344 O.49874572 RAD RADX http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Reports+Half-Year+Financial+Results+and+Business+Updates/25903754.html <p align="center"><em>Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases </em></p> <p align="center"><em>Interim data from additional Cohorts of the Phase 1 clinical trial of RAD 202 and RAD 204 in advanced solid tumors are expected in mid-2026</em></p> <p align="center"><em>Cash and cash equivalents of approximately $34.52 million provide runway into 2027 to advance pipeline of high value radiotherapeutic programs through key clinical and regulatory milestones</em></p> <p>SYDNEY, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Reports+Half-Year+Financial+Results+and+Business+Updates/25903754.html Wed, 28 Jan 2026 07:00:00 -0500 A.06822034 A.33615634 A.50205822 O.00061097 O.07116439 O.20026344 O.49874572 RAD RADX http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Reports+Half-Year+Financial+Results+and+Business+Updates/25903754.html <p align="center"><em>Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases </em></p> <p align="center"><em>Interim data from additional Cohorts of the Phase 1 clinical trial of RAD 202 and RAD 204 in advanced solid tumors are expected in mid-2026</em></p> <p align="center"><em>Cash and cash equivalents of approximately $34.52 million provide runway into 2027 to advance pipeline of high value radiotherapeutic programs through key clinical and regulatory milestones</em></p> <p>SYDNEY, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Reports+Half-Year+Financial+Results+and+Business+Updates/25903754.html Wed, 28 Jan 2026 07:00:00 -0500 A.06822034 A.33615634 A.50205822 O.00061097 O.07116439 O.20026344 O.49874572 RAD RADX